Mode
Text Size
Log in / Sign up

PRO and Serum Biomarker Models Predict Endoscopic Activity in Ulcerative ColitisCount Your Stools to Spot Flare-Ups Early

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider PRO and serum biomarker models as potential non-invasive tools for UC monitoring, pending prospective validation.

This retrospective multicenter cohort study developed and validated predictive models for endoscopic disease activity in patients with ulcerative colitis. The study included 173 patients in a training cohort and 124 patients in an external validation cohort. The models combined patient-reported outcomes (stool frequency or rectal bleeding) with serum biomarkers (CRP/TB ratio and platelet distribution width) to predict endoscopic activity, defined as a UCEIS score ≥1.

In the training cohort, Model A (stool frequency-based) and Model B (rectal bleeding-based) demonstrated excellent discriminative ability for endoscopic activity, with AUC values of 0.906 (95% CI 0.863–0.949) and 0.899 (95% CI 0.855–0.943), respectively. For predicting Mayo Endoscopic subscore categories, the models showed AUC values of 0.894 and 0.884. In the external validation cohort, performance remained strong with AUC values of 0.793 and 0.794 for endoscopic activity, and 0.769 and 0.758 for MES categories.

Safety and tolerability data were not reported. The study has several limitations inherent to its retrospective design, including potential selection bias and unmeasured confounding factors. The models require prospective validation in diverse clinical settings before clinical implementation can be considered.

The authors suggest these models have potential clinical utility as non-invasive tools for predicting endoscopic disease activity, which could help reduce the frequency of endoscopic procedures. However, clinicians should interpret these findings cautiously as the models have not yet been tested in prospective clinical practice, and endoscopic assessment remains the gold standard for disease activity evaluation in UC.

Imagine waking up and wondering if your gut is truly calm or hiding a storm. For people with ulcerative colitis, that worry is a daily reality.

Ulcerative colitis is a chronic condition that causes swelling and sores in the colon. It affects millions of people worldwide, yet many still struggle to know when their disease is truly quiet versus when it is flaring up.

Current treatments often rely on expensive colonoscopies to check for hidden inflammation. These procedures are invasive, costly, and not always available quickly. Patients often wait too long to get answers, letting symptoms worsen before they get help.

The Surprising Shift

Doctors used to believe that only a scope could tell the full story of disease activity. They assumed that if a patient felt okay, their colon was likely fine. But here is the twist: patients can feel better while dangerous inflammation still exists inside.

This new research changes that thinking. It shows that simple things you can count at home might be just as powerful as a lab test.

What Scientists Didn't Expect

The team looked at two main things: how often you use the bathroom and how much blood you see in your stool. They also looked at blood tests like C-reactive protein (CRP) and platelet distribution width (PDW).

Think of your body like a traffic system. When everything flows smoothly, there is no backup. But when an accident happens, traffic slows down. In the body, stool frequency and bleeding are the traffic jams that signal a problem.

The Study Snapshot

Researchers gathered data from 297 patients across multiple centers. They split the group into two teams: one to build the tool and another to test it. The goal was to create a simple score that anyone could use to guess if their colon was inflamed.

The results were very promising. The new scoring system could tell the difference between active disease and remission with high accuracy. In the first group, the tool was correct 90% of the time.

Even more importantly, it worked well in the second group of patients who were never seen by the researchers before. This proves the tool is reliable and not just a lucky guess.

But there is a catch. This tool is not a magic wand that replaces a doctor's visit. It is a helper to guide decisions.

While no specific doctor was quoted, the findings fit perfectly into the bigger picture of modern medicine. The medical world is moving toward "precision health," where simple data points guide big decisions.

Using patient-reported outcomes means listening to the person, not just the machine. This approach builds trust because patients feel heard. It also saves money by reducing unnecessary trips to the endoscopy suite.

If you live with ulcerative colitis, you might feel more confident tracking your own health. You can count your stools and note any bleeding at home.

However, do not stop seeing your doctor. Use these observations to prepare for your next appointment. Bring your notes to show your provider. This helps them decide if you need a scope or if you can wait.

This study looked at specific groups of patients. It did not test every possible cause of stomach pain. Also, the blood markers used are common and not unique to colitis. They must be combined with your stool counts to work well.

More research is needed to see how this tool works in different hospitals and with different types of patients. Doctors will likely start using these scores in daily practice soon.

This does not mean this treatment is available yet. It means a new way of thinking is arriving.

The future of managing ulcerative colitis looks brighter. By combining what you feel with what your blood shows, doctors can act faster. This leads to better control of the disease and fewer scary flare-ups.

Patients and doctors working together is the best path forward. Simple counts can lead to big improvements in quality of life.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background and aimThis study aims to develop a score system via noninvasive and reliable clinical tools for individuals to distinguish remission and active Ulcerative Colitis (UC).MethodsWe performed a retrospective multicenter study collecting 173 patients in the training cohort and 124 patients in the validation cohort with UC. Then we assessed the relationship between patient-reported outcomes (PROs) and serum indicators with endoscopic disease activity (defined as UCEIS ≥1). Univariate and multivariate logistic regression analyses were performed, with a stepwise backward selection approach used to select significant variables. Two predictive models were ultimately developed based on PROs and serum biomarkers. The performance of the models was evaluated through ROC curves, and calibration was assessed using Spiegelhalter’s Z-test.ResultsA total of 173 and 124 patients were enrolled in the training and validation groups, respectively. Univariate and multivariate analyses revealed that stool frequency (SF), rectal bleeding (RB), CRP/TB, and PDW were significantly associated with endoscopic active UC. Two predictive models were developed, with SF (model A) and RB (model B) combined with CRP/TB and PDW, respectively. Both models demonstrated excellent discriminative ability for endoscopic activity, with area under the ROC curve (AUC) values of 0.906 (95% CI 0.863–0.949) and 0.899 (95% CI 0.855–0.943) in the training cohort. In the external validation cohort, the AUC values were 0.793 and 0.794, showing similar strong discriminative ability. In the Mayo Endoscopic subscore (MES) system, model A and model B exhibited AUC values of 0.894 and 0.884 in the training cohort, and 0.769 and 0.758 in the validation cohort. Subgroup analysis based on disease severity further validated the models’ stability and reliability.ConclusionThe predictive models based on SF and RB developed in this study demonstrated good discriminative ability in predicting endoscopic activity in patients with UC. Both models performed well in the internal and external validation. Additional validation utilizing the MES and disease severity provided further evidence supporting the reliability and effectiveness of these models. These findings underscored the potential clinical utility of the SF- and RB-based models as valuable tools for predicting endoscopic disease activity in UC patients, which could facilitate more informed clinical decision-making and improve patient outcomes in the management of UC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.